Fostamatinib
- Generic Name
- Fostamatinib
- Brand Names
- Tavalisse, Tavlesse
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26FN6O9P
- CAS Number
- 901119-35-5
- Unique Ingredient Identifier
- SQ8A3S5101
- Background
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP . Fostamatinib has also been granted orphan drug status by the FDA .
Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.
- Indication
用于治疗对既往治疗反应不足的慢性免疫性血小板减少症（ITP）成年患者的血小板减少症。
- Associated Conditions
- Chronic immune thrombocytopenia
Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 8
- Registration Number
- NCT03991780
- Locations
- 🇬🇧
Imperial College NHS Healthcare Trust, London, United Kingdom
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
- Conditions
- Warm Antibody Autoimmune Hemolytic Anemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT03764618
- Locations
- 🇺🇸
Piedmont Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇦🇺Concord Repatriation General Hospital, Sydney, New South Wales, Australia
Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP
- Conditions
- Immune Thrombocytopenic Purpura
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Rigel Pharmaceuticals
- Registration Number
- NCT03363334
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2024-10-24
- Target Recruit Count
- 27
- Registration Number
- NCT03246074
- Locations
- 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)
- Conditions
- Warm Antibody Autoimmune Hemolytic Anemia
- Interventions
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT02612558
- Locations
- 🇺🇸
MidMichigan Health Cancer Center, Midland, Michigan, United States
🇺🇸Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
🇺🇸Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States
Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Stefanie Sarantopoulos, MD, PhD.
- Target Recruit Count
- 22
- Registration Number
- NCT02611063
- Locations
- 🇺🇸
Duke University of Medicine, Durham, North Carolina, United States
Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
- Conditions
- IGA Nephropathy
- Interventions
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Rigel Pharmaceuticals
- Registration Number
- NCT02433236
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
- Conditions
- IGA Nephropathy
- Interventions
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 76
- Registration Number
- NCT02112838
- Locations
- 🇺🇸
Southeast Renal Research Institute, Chattanooga, Tennessee, United States
🇦🇹Medical University Vienna, Nephrology, Vienna, Austria
🇨🇳China Medical University Hospital, Taichung, Taiwan
Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 198
- Registration Number
- NCT02092961
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 123
- Registration Number
- NCT02077192
- Locations
- 🇳🇱
HAGA ziekenhuis, Den Haag, NL, Netherlands
🇧🇬UMHAT Aleksandrovska, EAD, Sofia, Bulgaria
🇺🇸East Carolina University, Brody School of Medicine, Greenville, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.